ResearcherMoffitt Cancer CenterActive in the last 2 years
Aslamuzzaman Kazi
Matched on ORCID iD 0009-0005-7403-7468; OpenAlex author ID A5065882417. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. First author DOI 10.1016/j.ejca.2026.116255↗
- Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Co-author DOI 10.1158/2767-9764.crc-23-0222↗
- Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vignesh Vudatha · 2 shared papers, 2023–2026 · strength 0.46
- Paper FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. DOI 10.1016/j.ejca.2026.116255↗
- Paper Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Pa… DOI 10.1158/2767-9764.crc-23-0222↗
- Said M. Sebti · 2 shared papers, 2023–2026 · strength 0.46
- Paper FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. DOI 10.1016/j.ejca.2026.116255↗
- Paper Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Pa… DOI 10.1158/2767-9764.crc-23-0222↗
- Deblina Ghosh · 1 shared paper, 2026 · strength 0.32
- Christine A. Iacobuzio–Donahue · 1 shared paper, 2026 · strength 0.32
- Patrick W. Underwood · 2 shared papers, 2021–2023 · strength 0.25
- Paper Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Pa… DOI 10.1158/2767-9764.crc-23-0222↗
- Paper Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-20-4781↗
- Jason B. Fleming · 2 shared papers, 2021–2023 · strength 0.25
- Paper Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Pa… DOI 10.1158/2767-9764.crc-23-0222↗
- Paper Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-20-4781↗
- Jose Gilberto Trevino · 2 shared papers, 2021–2023 · strength 0.25
- Paper Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Pa… DOI 10.1158/2767-9764.crc-23-0222↗
- Paper Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-20-4781↗
- Perry Kennedy · 1 shared paper, 2023 · strength 0.14
- Kazim M. Husain · 1 shared paper, 2021 · strength 0.11
- Mokenge Peter Malafa · 1 shared paper, 2021 · strength 0.11
- Terence Marques Williams · 1 shared paper, 2021 · strength 0.11
- Saı̈d M. Sebti · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.